{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:46:13Z","timestamp":1791413173097,"version":"4.3.3"},"reference-count":24,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2012,6,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> This 3-year, prospective, multicenter trial assessed the safety and efficacy of deferasirox in low- or intermediate-1\u2013risk myelodysplastic syndrome (MDS). <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Eligible patients had serum ferritin \u2265 1,000 \u03bcg\/L and had received \u2265 20 units of RBCs with ongoing transfusion requirements. The starting dose of deferasirox was 20 mg\/kg\/d, with dose escalation up to 40 mg\/kg\/d permitted. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> A total of 176 patients were enrolled, and 173 patients received therapy. Median serum ferritin decreased 23% in the 53% of patients who completed 12 months of treatment (n = 91), 36.7% in patients who completed 2 years (n = 49), and 36.5% in patients who completed 3 years (n = 33) despite continued transfusion requirement. Reduction in serum ferritin significantly correlated with ALT improvement (P &lt; .001). Labile plasma iron (LPI) was measured quarterly during the first year of the study. Sixty-eight patients (39.3%) had elevated LPI at baseline. By week 13, LPI levels normalized in all patients with abnormal baseline level. Fifty-one (28%) of 173 patients experienced hematologic improvement by International Working Group 2006 criteria; of these, only seven patients received growth factors or MDS therapy. Over the 3-year study, 138 (79.8%) of 173 patients discontinued therapy, 43 patients (24.8%) because of adverse events or disease progression and 23 patients (13.2%) because of abnormal laboratory values. The most common drug-related adverse events were gastrointestinal disturbances and increased serum creatinine. There were 28 deaths, none of which were considered related to deferasirox. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Deferasirox reduces serum ferritin and LPI in transfusion-dependent patients with MDS. A subset of patients had an improvement in hematologic and hepatic parameters. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2010.34.1222","type":"journal-article","created":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T05:31:22Z","timestamp":1335850282000},"page":"2134-2139","source":"Crossref","is-referenced-by-count":148,"title":["Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion\u2013Dependent Patients With Myelodysplastic Syndrome"],"prefix":"10.1200","volume":"30","author":[{"given":"Alan F.","family":"List","sequence":"first","affiliation":[{"name":"Alan F. List, H. Lee Moffitt Cancer Center, Tampa, FL; Maria R. Baer, Roswell Park Cancer Institute, Buffalo; Azra Raza, Columbia University, New York, NY; David P. Steensma, Dana-Farber Cancer Institute, Boston, MA; Jason Esposito, Noelia Martinez-Lopez, and Carole Paley, Novartis Pharmaceuticals Corporation, East Hanover, NJ; John Feigert, Fairfax Northern Virginia Hematology\/Oncology, Arlington, VA; and Emmanuel Besa, Thomas Jefferson University, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[{"name":"Alan F. List, H. Lee Moffitt Cancer Center, Tampa, FL; Maria R. Baer, Roswell Park Cancer Institute, Buffalo; Azra Raza, Columbia University, New York, NY; David P. Steensma, Dana-Farber Cancer Institute, Boston, MA; Jason Esposito, Noelia Martinez-Lopez, and Carole Paley, Novartis Pharmaceuticals Corporation, East Hanover, NJ; John Feigert, Fairfax Northern Virginia Hematology\/Oncology, Arlington, VA; and Emmanuel Besa, Thomas Jefferson University, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Steensma","sequence":"additional","affiliation":[{"name":"Alan F. List, H. Lee Moffitt Cancer Center, Tampa, FL; Maria R. Baer, Roswell Park Cancer Institute, Buffalo; Azra Raza, Columbia University, New York, NY; David P. Steensma, Dana-Farber Cancer Institute, Boston, MA; Jason Esposito, Noelia Martinez-Lopez, and Carole Paley, Novartis Pharmaceuticals Corporation, East Hanover, NJ; John Feigert, Fairfax Northern Virginia Hematology\/Oncology, Arlington, VA; and Emmanuel Besa, Thomas Jefferson University, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Raza","sequence":"additional","affiliation":[{"name":"Alan F. List, H. Lee Moffitt Cancer Center, Tampa, FL; Maria R. Baer, Roswell Park Cancer Institute, Buffalo; Azra Raza, Columbia University, New York, NY; David P. Steensma, Dana-Farber Cancer Institute, Boston, MA; Jason Esposito, Noelia Martinez-Lopez, and Carole Paley, Novartis Pharmaceuticals Corporation, East Hanover, NJ; John Feigert, Fairfax Northern Virginia Hematology\/Oncology, Arlington, VA; and Emmanuel Besa, Thomas Jefferson University, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Esposito","sequence":"additional","affiliation":[{"name":"Alan F. List, H. Lee Moffitt Cancer Center, Tampa, FL; Maria R. Baer, Roswell Park Cancer Institute, Buffalo; Azra Raza, Columbia University, New York, NY; David P. Steensma, Dana-Farber Cancer Institute, Boston, MA; Jason Esposito, Noelia Martinez-Lopez, and Carole Paley, Novartis Pharmaceuticals Corporation, East Hanover, NJ; John Feigert, Fairfax Northern Virginia Hematology\/Oncology, Arlington, VA; and Emmanuel Besa, Thomas Jefferson University, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Martinez-Lopez","sequence":"additional","affiliation":[{"name":"Alan F. List, H. Lee Moffitt Cancer Center, Tampa, FL; Maria R. Baer, Roswell Park Cancer Institute, Buffalo; Azra Raza, Columbia University, New York, NY; David P. Steensma, Dana-Farber Cancer Institute, Boston, MA; Jason Esposito, Noelia Martinez-Lopez, and Carole Paley, Novartis Pharmaceuticals Corporation, East Hanover, NJ; John Feigert, Fairfax Northern Virginia Hematology\/Oncology, Arlington, VA; and Emmanuel Besa, Thomas Jefferson University, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Paley","sequence":"additional","affiliation":[{"name":"Alan F. List, H. Lee Moffitt Cancer Center, Tampa, FL; Maria R. Baer, Roswell Park Cancer Institute, Buffalo; Azra Raza, Columbia University, New York, NY; David P. Steensma, Dana-Farber Cancer Institute, Boston, MA; Jason Esposito, Noelia Martinez-Lopez, and Carole Paley, Novartis Pharmaceuticals Corporation, East Hanover, NJ; John Feigert, Fairfax Northern Virginia Hematology\/Oncology, Arlington, VA; and Emmanuel Besa, Thomas Jefferson University, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Feigert","sequence":"additional","affiliation":[{"name":"Alan F. List, H. Lee Moffitt Cancer Center, Tampa, FL; Maria R. Baer, Roswell Park Cancer Institute, Buffalo; Azra Raza, Columbia University, New York, NY; David P. Steensma, Dana-Farber Cancer Institute, Boston, MA; Jason Esposito, Noelia Martinez-Lopez, and Carole Paley, Novartis Pharmaceuticals Corporation, East Hanover, NJ; John Feigert, Fairfax Northern Virginia Hematology\/Oncology, Arlington, VA; and Emmanuel Besa, Thomas Jefferson University, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Besa","sequence":"additional","affiliation":[{"name":"Alan F. List, H. Lee Moffitt Cancer Center, Tampa, FL; Maria R. Baer, Roswell Park Cancer Institute, Buffalo; Azra Raza, Columbia University, New York, NY; David P. Steensma, Dana-Farber Cancer Institute, Boston, MA; Jason Esposito, Noelia Martinez-Lopez, and Carole Paley, Novartis Pharmaceuticals Corporation, East Hanover, NJ; John Feigert, Fairfax Northern Virginia Hematology\/Oncology, Arlington, VA; and Emmanuel Besa, Thomas Jefferson University, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1182\/blood.V104.11.4716.4716","volume":"104","author":"Brechignac S","year":"2004","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.01.002"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802565867"},{"key":"B4","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood.V112.11.2677.2677","volume":"112","author":"Della Porta MG","year":"2008","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(09)70179-1"},{"key":"B6","first-page":"143","volume":"28","author":"Jaeger M","year":"1992","journal-title":"Drugs Today"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.7038"},{"key":"B8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1182\/blood.V110.11.249.249","volume":"110","author":"Rose C","year":"2007","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.12.004"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21192"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.105"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-008-0120-5"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2004.10.003"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.2.705.bloodjournal882705"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000158631"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb06411.x"},{"key":"B17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood.V112.11.633.633","volume":"112","author":"Gattermann N","year":"2008","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.2912.2912"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041534"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(02)80116-0"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411002"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.03.009"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2010.34.1222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:29:30Z","timestamp":1653517770000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2010.34.1222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,10]]},"references-count":24,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2012,6,10]]}},"alternative-id":["10.1200\/JCO.2010.34.1222"],"URL":"https:\/\/doi.org\/10.1200\/jco.2010.34.1222","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,10]]}}}